Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 61
- Registration Number
- NCT05765825
- Locations
- 🇨🇳
GuiZhou Provincial People's Hospital, Guiyang, China
🇨🇳Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
🇨🇳Chongqing University cancer hospital, Chongqing, Chongqing, China
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: BendamustineDrug: Brentuximab VedotinDrug: CarboplatinProcedure: Computed TomographyDrug: EtoposideDrug: GemcitabineDrug: IfosfamideDrug: Pegylated Liposomal Doxorubicin HydrochlorideProcedure: Positron Emission TomographyBiological: PembrolizumabRadiation: Radiation TherapyOther: Transplant ConditioningDrug: Vinorelbine
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT05711628
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Conditions
- Interventions
- Procedure: Biospecimen CollectionBiological: Bleomycin SulfateProcedure: Computed TomographyDrug: Brentuximab VedotinDrug: DacarbazineDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideOther: Fludeoxyglucose F-18Procedure: Magnetic Resonance ImagingDrug: EtoposideProcedure: Positron Emission TomographyDrug: Etoposide PhosphateOther: Questionnaire AdministrationBiological: NivolumabDrug: Vinblastine SulfateRadiation: Involved-site Radiation TherapyDrug: PrednisoloneDrug: PrednisoneDrug: Procarbazine HydrochlorideDrug: Vincristine Sulfate
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1875
- Registration Number
- NCT05675410
- Locations
- 🇺🇸
Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-01-03
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 19
- Registration Number
- NCT05665075
- Locations
- 🇨🇳
The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
Natural Killer(NK) Cell Therapy in r/r AML
- Conditions
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-01-03
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 18
- Registration Number
- NCT05665114
- Locations
- 🇨🇳
The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT05664971
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer
- Conditions
- Interventions
- Drug: CarboplatinDrug: CisplatinProcedure: Computed TomographyBiological: DurvalumabDrug: EtoposideRadiation: Image Guided Radiation TherapyDrug: PaclitaxelDrug: PemetrexedProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 474
- Registration Number
- NCT05624996
- Locations
- 🇺🇸
UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
🇺🇸Ascension Borgess Hospital, Kalamazoo, Michigan, United States
🇺🇸Benefis Sletten Cancer Institute, Great Falls, Montana, United States
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 300
- Registration Number
- NCT05605899
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Joseph Tuscano
- Target Recruit Count
- 24
- Registration Number
- NCT05600686
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT05595460
- Locations
- 🇵🇷
Research Facility, San Juan, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.